Inicio › Neoplasias mieloproliferativas › Texas › Houston
Ensayos clínicos de Neoplasias mieloproliferativas en Houston, TX
16 estudios para Neoplasias mieloproliferativas buscan participantes en centros de Houston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ReclutandoFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
ReclutandoFase 1
- The University of Texas, MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
ReclutandoEstudio observacional
- Texas Children's Hospital, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
ReclutandoFase 1/2
- MD Anderson, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
ReclutandoFase 1
- M D Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
ReclutandoFase 2
- The University of Texas MD Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
ReclutandoFase 1/2
- M D Anderson Cancer Center, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
ReclutandoFase 2
- M D Anderson Cancer Center, Houston
Project: Every Child for Younger Patients With Cancer
ReclutandoEstudio observacional
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
ReclutandoFase 1
- University of Texas M. D. Anderson Cancer Center, Houston
Asciminib Roll-over Study
ReclutandoFase 4
- Uni Of TX MD Anderson Cancer Cntr, Houston
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
ReclutandoFase 2
- M D Anderson Cancer Center, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
ReclutandoFase 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
ReclutandoFase 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
ReclutandoFase 1
- The University of Texas MD Anderson Cancer Center, Houston
Ensayos de Neoplasias mieloproliferativas en otras ciudades
- New York City, NY15 estudios
- Boston, MA14 estudios
- Milwaukee, WI10 estudios
- Miami, FL10 estudios
- Durham, NC9 estudios
- Baldwin Park, CA9 estudios
- Seattle, WA9 estudios
- Chicago, IL9 estudios
- Portland, OR8 estudios
- Cleveland, OH8 estudios
- Atlanta, GA8 estudios
- Tampa, FL8 estudios
Otros estudios en Houston
- Cáncer de pulmón de células no pequeñas145 estudios
- Cáncer de seno126 estudios
- Cáncer (todos los tipos)121 estudios
- Cáncer metastásico104 estudios
- Cáncer del colon y del recto102 estudios
- Cáncer de ovario89 estudios
- Leucemia mielógena aguda85 estudios
- Cáncer de pulmón78 estudios
- Cáncer de próstata76 estudios
- Cáncer de endometrio68 estudios
- Cáncer de páncreas61 estudios
- Melanoma59 estudios
De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.